Immuron Ltd

Immuron Limited is an Australian biopharmaceutical company engaged in developing and commercializing orally delivered polyclonal antibody therapies targeting mucosal surfaces in the gastrointestinal tract. The company focuses on addressing conditions such as travelers' diarrhea, irritable bowel syndrome, and enteric infections caused by pathogens like Enterotoxigenic Escherichia coli and Clostridioides difficile. Its commercial offerings include Travelan, an over-the-counter formulation designed to lower the incidence of travelers' diarrhea, and ProIBS, an orally administered product containing AVH200 that creates a protective hydrogel barrier to soothe irritable bowel syndrome symptoms. Operating across hyper-immune products and research and development divisions, the business primarily supplies retail consumers and travel health markets through retail pharmacies, clinical practitioners, and online channels.

Headquartered in Carlton South, Victoria, Australia, Immuron markets its commercial products across several international jurisdictions. The enterprise distributes Travelan through pharmacies throughout Australia, sells the product as a licensed natural health item in Canada, and distributes it as a dietary supplement within the United States. ProIBS is marketed to patients and consumers in Australia.

Summary of the business section of Immuron's latest annual report, written by StockData.

“As of June 30, 2026, we had seven full-time employees and one part time employee.”